427 related articles for article (PubMed ID: 36426365)
1. Mesenchymal stromal cells as treatment for acute respiratory distress syndrome. Case Reports following hematopoietic cell transplantation and a review.
Sadeghi B; Ringdén O; Gustafsson B; Castegren M
Front Immunol; 2022; 13():963445. PubMed ID: 36426365
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome.
Ringdén O; Moll G; Gustafsson B; Sadeghi B
Front Immunol; 2022; 13():839844. PubMed ID: 35371003
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal Stromal Cells in Pediatric Hematopoietic Cell Transplantation a Review and a Pilot Study in Children Treated With Decidua Stromal Cells for Acute Graft-versus-Host Disease.
Ringdén O; Gustafsson B; Sadeghi B
Front Immunol; 2020; 11():567210. PubMed ID: 33193339
[TBL] [Abstract][Full Text] [Related]
5. Placenta-Derived Decidua Stromal Cells: A New Frontier in the Therapy of Acute Graft-Versus-Host Disease.
Ringdén O; Sadeghi B
Stem Cells; 2024 Apr; 42(4):291-300. PubMed ID: 38204331
[TBL] [Abstract][Full Text] [Related]
6. Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment.
Aghayan HR; Salimian F; Abedini A; Fattah Ghazi S; Yunesian M; Alavi-Moghadam S; Makarem J; Majidzadeh-A K; Hatamkhani A; Moghri M; Danesh A; Haddad-Marandi MR; Sanati H; Abbasvandi F; Arjmand B; Azimi P; Ghavamzadeh A; Sarrami-Forooshani R
Stem Cell Res Ther; 2022 Jul; 13(1):365. PubMed ID: 35902979
[TBL] [Abstract][Full Text] [Related]
7. Potential application of mesenchymal stromal cells as a new therapeutic approach in acute respiratory distress syndrome and pulmonary fibrosis.
Gazzaniga G; Voltini M; Carletti A; Lenta E; Meloni F; Briganti DF; Avanzini MA; Comoli P; Belliato M
Respir Res; 2024 Apr; 25(1):170. PubMed ID: 38637860
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential.
Gorman E; Millar J; McAuley D; O'Kane C
Expert Rev Respir Med; 2021 Mar; 15(3):301-324. PubMed ID: 33172313
[No Abstract] [Full Text] [Related]
9. Feasibility Study of Cord Tissue Derived Mesenchymal Stromal Cells in COVID-19-Related Acute Respiratory Distress Syndrome.
Shaz BH; Kraft BD; Troy JD; Poehlein E; Chen L; Cheatham L; Manyara R; Hanafy K; Brown L; Scott M; Palumbo R; Vrionis F; Kurtzberg J
Stem Cells Transl Med; 2023 Apr; 12(4):185-193. PubMed ID: 36929827
[TBL] [Abstract][Full Text] [Related]
10. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial.
Wilson JG; Liu KD; Zhuo H; Caballero L; McMillan M; Fang X; Cosgrove K; Vojnik R; Calfee CS; Lee JW; Rogers AJ; Levitt J; Wiener-Kronish J; Bajwa EK; Leavitt A; McKenna D; Thompson BT; Matthay MA
Lancet Respir Med; 2015 Jan; 3(1):24-32. PubMed ID: 25529339
[TBL] [Abstract][Full Text] [Related]
11. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study.
Zheng G; Huang L; Tong H; Shu Q; Hu Y; Ge M; Deng K; Zhang L; Zou B; Cheng B; Xu J
Respir Res; 2014 Apr; 15(1):39. PubMed ID: 24708472
[TBL] [Abstract][Full Text] [Related]
12. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.
Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF
Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473
[TBL] [Abstract][Full Text] [Related]
13. Intravenous Autologous Bone Marrow-derived Mesenchymal Stromal Cells Delay Acute Respiratory Distress Syndrome in Swine.
Batchinsky AI; Roberts TR; Antebi B; Necsoiu C; Choi JH; Herzig M; Cap AP; McDaniel JS; Rathbone CR; Chung KK; Cancio LC
Am J Respir Crit Care Med; 2023 Dec; 208(12):1283-1292. PubMed ID: 37797214
[No Abstract] [Full Text] [Related]
14. Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial.
Monsel A; Hauw-Berlemont C; Mebarki M; Heming N; Mayaux J; Nguekap Tchoumba O; Diehl JL; Demoule A; Annane D; Marois C; Demeret S; Weiss E; Voiriot G; Fartoukh M; Constantin JM; Mégarbane B; Plantefève G; Malard-Castagnet S; Burrel S; Rosenzwajg M; Tchitchek N; Boucher-Pillet H; Churlaud G; Cras A; Maheux C; Pezzana C; Diallo MH; Ropers J; Menasché P; Larghero J;
Crit Care; 2022 Feb; 26(1):48. PubMed ID: 35189925
[TBL] [Abstract][Full Text] [Related]
15. Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS.
Häberle H; Magunia H; Lang P; Gloeckner H; Körner A; Koeppen M; Backchoul T; Malek N; Handgretinger R; Rosenberger P; Mirakaj V
J Intensive Care Med; 2021 Jun; 36(6):681-688. PubMed ID: 33663244
[TBL] [Abstract][Full Text] [Related]
16. Fresh and Cryopreserved Human Umbilical-Cord-Derived Mesenchymal Stromal Cells Attenuate Injury and Enhance Resolution and Repair following Ventilation-Induced Lung Injury.
Horie S; Gonzalez H; Brady J; Devaney J; Scully M; O'Toole D; Laffey JG
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884645
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial.
Kaffash Farkhad N; Sedaghat A; Reihani H; Adhami Moghadam A; Bagheri Moghadam A; Khadem Ghaebi N; Khodadoust MA; Ganjali R; Tafreshian AR; Tavakol-Afshari J
Stem Cell Res Ther; 2022 Jun; 13(1):283. PubMed ID: 35765103
[TBL] [Abstract][Full Text] [Related]
18. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
[TBL] [Abstract][Full Text] [Related]
19. Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial.
Zarrabi M; Shahrbaf MA; Nouri M; Shekari F; Hosseini SE; Hashemian SR; Aliannejad R; Jamaati H; Khavandgar N; Alemi H; Madani H; Nazari A; Amini A; Hassani SN; Abbasi F; Jarooghi N; Fallah N; Taghiyar L; Ganjibakhsh M; Hajizadeh-Saffar E; Vosough M; Baharvand H
Stem Cell Res Ther; 2023 Jun; 14(1):169. PubMed ID: 37365605
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic mechanisms of mesenchymal stem cells in acute respiratory distress syndrome reveal potentials for Covid-19 treatment.
Wang W; Lei W; Jiang L; Gao S; Hu S; Zhao ZG; Niu CY; Zhao ZA
J Transl Med; 2021 May; 19(1):198. PubMed ID: 33971907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
